How full is our antihypertensives pipeline?

Journal of Pharmacology and Pharmacotherapeutics

Volumn 3, Issue 1, 2012, Pages 7-11

  Gude, Dilip ^a  

^a Medwin Hospital   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANTIHYPERTENSIVE AGENT; AZILSARTAN MEDOXOMIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATESTATIN; CILNIDIPINE; CLEVIDIPINE; DIMINAZENE ACETURATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EBELACTONE B; EPLERENONE; FIMASARTAN; GUANYLATE CYCLASE ACTIVATOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IPTAKALIM; LEMAKALIM; LOSARTAN; MAGNESIUM; MOXONIDINE; NAFTOPIDIL; NIFEDIPINE; OLMESARTAN; PEPTIDE HYDROLASE INHIBITOR; RILMAKALIM; RILMENIDINE; ROSTAFUROXIN; SPIRONOLACTONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; VASOPEPTIDASE INHIBITOR;

ANGIONEUROTIC EDEMA; COUGHING; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOALGESIA; HYPOTENSION; NONHUMAN; NOTE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84878692558     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.92492     Document Type: Note

References (44)

1. Gao S, Long CL, Wang RH, Wang H. K(ATP) activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function. Cardiovasc Res 2009; 83: 444-56.
2. Polat B, Tufan H, Danisman N. Vasorelaxant effect of levcromakalim on isolated umbilical arteries of preeclamptic women. Eur J Obstet Gynecol Reprod Biol 2007; 134: 169-73.
3. Novaković A, Gojković-Bukarica L, Beleslin-Cokić B, Japundzić-Zigon N, Sajić Z, Nezić D, et al. Differential antivasoconstrictor effects of levcromakalim and rilmakalim on the isolated human mammary artery and saphenous vein. J Pharmacol Sci 2003; 92: 108-14.
4. McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008; 1: 17-24.
5. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-46.
6. Flynn JT. Not ready for prime time: Aliskiren for treatment of hypertension or proteinuria in children. Pediatr Nephrol 2011; 26: 491-2.
7. Bloch MJ, Basile JN. Combination angiotensin receptor blocker-neutral endopeptidase inhibitor provides additive blood pressure reduction over angiotensin receptor blocker alone. J Clin Hypertens (Greenwich) 2010; 12: 809-12.
8. Daull P, Jeng AY, Battistini B. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases. J Cardiovasc Pharmacol 2007; 50: 247-56.
9. Davidson EP, Kleinschmidt TL, Oltman CL, Lund DD, Yorek MA. Treatment of streptozotocin-induced diabetic rats with AVE7688, a vasopeptidase inhibitor: Effect on vascular and neural disease. Diabetes 2007; 56: 355-62.
10. White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57: 413-20.
11. Na Y, Lee EK. PCV112 Extension of meta-analysis in comparing of fimasartan with losartan in blood pressure lowering effect. Value Health 2011; 14: A53.
12. Bhuyan BJ, Mugesh G. Synthesis, characterization and antioxidant activity of angiotensin converting enzyme inhibitors. Org Biomol Chem 2011; 9: 1356-65.
13. Nishiyama A, Hasegawa K, Diah S, Hitomi H. New approaches to blockade of the renin-angiotensin-aldosterone system: Mineralocorticoid-receptor blockers exert antihypertensive and renoprotective effects independently of the renin-angiotensin system. J Pharmacol Sci 2010; 113: 310-4.
14. Savoia C, Touyz RM, Amiri F, Schiffrin EL. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 2008; 51: 432-9.
15. Ohtani T, Ohta M, Yamamoto K, Mano T, Sakata Y, Nishio M, et al. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol 2007; 292: R946-54.
16. Burke SL, Head GA. Cardiac and renal baroreflex control during stress in conscious renovascular hypertensive rabbits: Effect of rilmenidine. J Hypertens 2009; 27: 132-41.
17. Hausberg M, Tokmak F, Pavenstädt H, Krämer BK, Rump LC. Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease. J Hypertens 2010; 28: 1920-7.
18. Manetti F, Corelli F, Strappaghetti G, Botta M. Arylpiperazines with affinity toward alpha (1)-adrenergic receptors. Curr Med Chem 2002; 9: 1303-21.
19. Löhn M, Muzzulini U, Essin K, Tsang SY, Kirsch T, Litteral J, et al. Cilnidipine is a novel slow-acting blocker of vascular L-type calcium channels that does not target protein kinase C. J Hypertens 2002; 20: 885-93.
20. Toba H, Yoshida M, Tojo C, Nakano A, Oshima Y, Kojima Y, et al. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetatesalt hypertensive rats. Hypertens Res 2011; 34: 521-9.
21. Fan Y, Mizutani T, Matsubara K, Nakano D, Kobori H, Fujita T, et al. Cilnidipine elicits renoprotective effects through reductions in intrarenal renin-angiotensin system and oxidative stress in shr/nd rats. NDT Plus 2009; 2(Suppl 2): 985.
22. Ndefo UA, Erowele GI, Ebiasah R, Green W. Clevidipine: A new intravenous option for the management of acute hypertension. Am J Health Syst Pharm 2010; 67: 351-60.
23. Hatzistavri LS, Sarafidis PA, Georgianos PI, Tziolas IM, Aroditis CP, Zebekakis PE, et al. Oral magnesium supplementation reduces ambulatory blood pressure in patients with mild hypertension. Am J Hypertens 2009; 22: 1070-5.
24. Guerrero-Romero F, Rodríguez-Morán M. The effect of lowering blood pressure by magnesium supplementation in diabetic hypertensive adults with low serum magnesium levels: A randomized, double-blind, placebocontrolled clinical trial. J Hum Hypertens 2009; 23: 245-51.
25. Ferrari P. Rostafuroxin: An ouabain-inhibitor counteracting specific forms of hypertension. Biochim Biophys Acta 2010; 1802: 1254-8.
26. Kuznetsova T, Manunta P, Casamassima N, Messaggio E, Jin Y, Thijs L, et al. Left ventricular geometry and endogenous ouabain in a Flemish population. J Hypertens 2009; 27: 1884-91.
27. Gjymishka A, Kulemina LV, Shenoy V, Kayovich MJ, Ostrov DA, Raizada MK. Diminazene Aceturate Is an ACE2 Activator and a Novel Antihypertensive Drug. FASEB J 2010; 24: 1032-3.
28. Ferreira AJ, Shenoy V, Yamazato Y, Sriramula S, Francis J, Yuan L, et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179: 1048-54.
29. Raizada MK, Ferreira AJ. ACE2: A new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol 2007; 50: 112-9.
30. Katori M, Majima M. A Novel Category of Anti-Hypertensive Drugs for Treating Salt-Sensitive Hypertension on the Basis of a New Development Concept. Pharmaceuticals 2010; 3: 59-109.
31. Ito H, Majima M, Nakajima S, Hayashi I, Katori M, Izumi T. Effect of prolonged administration of a urinary kinase inhibitor, ebelactone B on the development of deoxycorticosterone acetate-salt hypertension in rats. Br J Pharmacol 1999; 126: 613-20.
32. Savergnini SQ, Beiman M, Lautner RQ, de Paula-Carvalho V, Allahdadi K, Pessoa DC, et al. Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension 2010; 56: 112-20.
33. Angelone T, Quintieri AM, Brar BK, Limchaiyawat PT, Tota B, Mahata SK, et al. The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology 2008; 149: 4780-93.
34. Penna C, Alloatti G, Gallo MP, Cerra MC, Levi R, Tullio F, et al. Catestatin improves post-ischemic left ventricular function and decreases ischemia/ reperfusion injury in heart. Cell Mol Neurobiol 2010; 30: 1171-9.
35. Priviero FB, Webb RC. Heme-dependent and independent soluble guanylate cyclase activators and vasodilation. J Cardiovasc Pharmacol. 2010; 56: 229-33.
36. Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA, et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J 2010; 24: 3770-81.
37. Loot AE, Fleming I. Cytochrome P450-derived epoxyeicosatrienoic acids and pulmonary hypertension: Central role of transient receptor potential C6 channels. J Cardiovasc Pharmacol 2011; 57: 140-7.
38. Certíková Chábová V, Walkowska A, Kompanowska-Jezierska E, Sadowski J, Kujal P, Vernerová Z, et al. Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. Clin Sci (Lond) 2010; 118: 617-32.
39. Mancia G, Parati G, Revera M, Bilo G, Giuliano A, Veglia F, et al. Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: Evidence from PHYLLIS randomised double blind trial. BMJ 2010; 340: c1197.
40. Feldstein CA. Statins in hypertension: Are they a new class of antihypertensive agents? Am J Ther 2010; 17: 255-62.
41. Phisitkul S. CYT-006-AngQb, a vaccine against angiotensin II for the potential treatment of hypertension. Curr Opin Investig Drugs 2009; 10: 269-75.
42. Broeckel U, Stoll M, Hein L. The identification of phosducin as a novel candidate gene for hypertension and its role in sympathetic activation. Curr Opin Nephrol Hypertens 2011; 20: 118-24.
43. Preston RA, White WB, Pitt B, Bakris G, Norris PM, Hanes V. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005; 18: 797-804.
44. Thompson KA, Kar S, Makkar R, Victor RG. Drug-resistant hypertension: Is renal sympathetic denervation the answer? Curr Cardiol Rep 2011; 13: 93-5.